Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 115 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Influenza Vaccine Effectiveness Clear all
Completed Phase 3 Interventional

Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

NCT02612922
View directory record Official record
Conditions
Influenza
Interventions
Nitazoxanide, Placebo
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
12 Years to 65 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Hot Springs, Arkansas • Anaheim, California • Fresno, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 22, 2026, 10:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

NCT03694392
View directory record Official record
Conditions
Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction, Congestive Heart Failure, Stroke
Interventions
Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 64 Years
Enrollment
2,776,278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms

NCT03653364
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 1 Year
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Jonesboro, Arkansas • Tampa, Florida • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults

NCT02008344
View directory record Official record
Conditions
Influenza
Interventions
favipiravir, placebo
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
147
States / cities
Birmingham, Alabama • Huntsville, Alabama • Camp Verde, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

NCT02566265
View directory record Official record
Conditions
Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
Interventions
Fluzone High Dose Vaccine, Standard of care/Placebo
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

NCT01052480
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Anti-Influenza Immune Plasma, Standard Care
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
35
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Effectiveness of Influenza Vaccine Reminder Systems

NCT01852656
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease
Interventions
Postcard and IVR Reminder Group, Postcard Only Reminder Group, IVR Only Reminder Group
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
19 Years to 64 Years
Enrollment
12,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Sep 22, 2026, 10:05 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

BPL-1357 Against H1N1 Influenza Virus Challenge

NCT07215858
View directory record Official record
Conditions
Influenza, Human
Interventions
BPL-1357 IM, BPL-1357 IN, Placebo IM, Placebo IN
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Not applicable Interventional Results available

STIP: Statin Trial for Influenza Patients

NCT00970606
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
Interventions
Rosuvastatin (crestor), Placebo
Drug
Lead sponsor
Gordon Bernard
Other
Eligibility
13 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Little Rock, Alaska • Phoenix, Arizona • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

NCT01964989
View directory record Official record
Conditions
Influenza Virus
Interventions
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 71 Months
Enrollment
10,644 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
91
States / cities
Chandler, Arizona • Harrisburg, Arkansas • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 22, 2026, 10:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vaccine Efficacy in Diabetic and Elderly Patients

NCT02675608
View directory record Official record
Conditions
Inflammation
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness

NCT04043923
View directory record Official record
Conditions
Influenza -Like Illness
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

NCT00800605
View directory record Official record
Conditions
Influenza
Interventions
Vero cell-derived, trivalent, seasonal influenza vaccine, Placebo: Phosphate-buffered saline
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
7,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Sacramento, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model

NCT02371668
View directory record Official record
Conditions
H1N1 Influenza Healthy Volunteers
Interventions
CR6261, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 22, 2026, 10:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
1,500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Recombinant Influenza Vaccination in U.S. Nursing Homes

NCT03965195
View directory record Official record
Conditions
Influenza, Influenza -Like Illness, Influenza, Human
Interventions
Recombinant Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
18 Years to 120 Years
Enrollment
1,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Results available

Rapid Empiric Treatment With Oseltamivir Study (RETOS)

NCT01248715
View directory record Official record
Conditions
Influenza, Pneumonia
Interventions
oseltamivir
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
1,107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

A Clinical Trial of KT07 Capsule in the U.S.A

NCT02867358
View directory record Official record
Conditions
Influenza, Human
Interventions
KT07 Capsule, Placebo
Drug · Other
Lead sponsor
Yiling Pharmaceutical Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
81
States / cities
Birmingham, Alabama • Pelham, Alabama • Tolleson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

NCT02287467
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 22, 2026, 10:05 PM EDT
Withdrawn Phase 2 Interventional

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

NCT01992276
View directory record Official record
Conditions
Influenza
Interventions
CR8020, CR6261, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

The Respiratory Protection Effectiveness Clinical Trial

NCT01249625
View directory record Official record
Conditions
Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus, Rhinovirus
Interventions
N95 Respirator, Medical/surgical mask
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
2,862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
7
States / cities
Aurora, Colorado • Denver, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

NCT01740063
View directory record Official record
Conditions
Influenza
Interventions
DAS181-F02 formulation, DAS181-F04 formulation, Placebo
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2019 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

NCT00192218
View directory record Official record
Conditions
Influenza
Interventions
FluMist
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
3,022 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2008 · Synced Sep 22, 2026, 10:05 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

High-Dose Influenza Vaccine in Nursing Homes

NCT01815268
View directory record Official record
Conditions
Influenza
Interventions
HD Vaccine, SD Vaccine, Free Vaccine, Usual Care
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
823 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
3
States / cities
Cleveland, Ohio • Providence, Rhode Island • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 22, 2026, 10:05 PM EDT